Toronto, ON (PRWEB) May 25, 2021 Clinical development has more partnerships and collaborations than ever before with many companies acquiring assets from
Search jobs 24-May-2021 Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3
DGAP-News: ABIVAX / Key word(s): Study results
24.05.2021 / 18:30
The issuer is solely responsible for the content of this announcement.
Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis
and plans to proceed to phase 3
Primary endpoint (statistically significant reduction of Modified Mayo Score
[1]) was met with once-daily ABX464 (25mg, 50mg, 100mg) at week 8 in these 254 patients randomized, double-blind and placebo-controlled clinical trial (p
In September 2020, Acasti engaged Oppenheimer & Company Inc to act as its financial advisor to assist in the review aimed at enhancing shareholder value
Biostatisticians draft blueprints for COVID-19 vax trials
Hutch group applies skills honed during decades of HIV prevention trials to bring about safe and effective vaccines for a new pandemic February 18, 2021 • By Sabin Russell / Fred Hutch News Service
Dr. Peter Gilbert (left) leads a team of Fred Hutch biostatisticians that pivoted to COVID-19 vaccine trial design. Dr. Holly Janes (right) is a co-principal investigator with Gilbert at the Statistical and Data Management Center for the HIV Vaccine Trials Network.
Dr. Peter Gilbert (top) leads a team of Fred Hutch biostatisticians that pivoted to COVID-19 vaccine trial design. Dr. Holly Janes (below) is a co-principal investigator with Gilbert at the Statistical and Data Management Center for the HIV Vaccine Trials Network.